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SUMMARY
Background
There is a renewed interest in use of combination therapies in
treatment-naı¨ve chronic hepatitis B (CHB) because of limitations of
monotherapies.
Aim
To discuss the current status of combination therapies in treatment-
naı¨ve CHB.
Methods
PubMed search was done using ‘combination’, ‘sequential’ and ‘chronic
hepatitis B’ as the search terms.
Results
The two most popular combination therapies include ‘combination of
nucleos(t)ide analogues’ and ‘combination of interferons and nucle-
os(t)ide analogues’. Combination therapies using two nucleos(t)ide ana-
logues do not lead to higher long-term efficacy. However, addition of a
nucleos(t)ide analogue with a good resistance profile to a nucleos(t)ide
analogue with a lower genetic barrier to resistance decreases the risk of
emergent resistance to the latter. Greater sustained virological, biochem-
ical and seroconversion rates are observed with addition of lamivudine
to conventional interferon, but pegylated-interferon monotherapy is
equally effective as combination with lamivudine. Again, resistance to
lamivudine is lower with its combination with interferons.
Conclusions
The answer to the question whether hepatitis B can be treated better
with combination or monotherapy remains largely unknown. Additional
trials are warranted of combination therapies of peginterferon and
potent nucleos(t)ide analogues or therapies with the combined use of
nucleos(t)ide analogues or immunomodulators.
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INTRODUCTION
More than 400 million people worldwide are chroni-
cally infected with hepatitis B virus (HBV).1 Effective
therapy is necessary to prevent the progression of
chronic hepatitis B (CHB) to cirrhosis, hepatocellular
carcinoma and death.
Agents currently used for the treatment of chronic
HBV infection are divided into two main groups based
on their primary mode of action: the immunomodula-
tors e.g. interferons (IFNs), thymosin, interleukins, etc.
and the nucleos(t)ide analogues.
IFNs [including standard IFN and pegylated IFN
(peg-IFN)] and other immunomodulators act by pro-
moting cytotoxic T-cell activity for lysis of infected
hepatocytes and by stimulating cytokine production
for control of viral replication. The introduction of
nucleos(t)ide analogues (lamivudine, adefovir, enteca-
vir, telbuvidine, tenofovir, etc.) heralded a new era in
the treatment of CHB, and provided a safe, effective
and well-tolerated alternative to IFN. Nucleos(t)ide
analogues target the reverse transcriptase of HBV
and are potent inhibitors of viral replication.
Although treatment with nucleos(t)ide analogues pro-
foundly suppresses serum HBV DNA levels and
response can be maintained over prolonged periods
with ongoing therapy, response to treatment may not
be durable in a large proportion of patients after dis-
continuation of therapy, indicating the necessity for
a long-term, and maybe indefinite, treatment.2, 3
However, development of anti-viral resistance is a
major limitation to long-term efficacy of nucle-
os(t)ide analogues.4
HBV therapy must provide potent long-term viral
suppression and at the same time avoid development
of resistance. To prevent development of anti-viral
drug resistance, a judicious use of nucleos(t)ide ana-
logues in patients with chronic HBV infection is
needed.5 The first manifestation of anti-viral resistance
is virological breakthrough, which is defined as
a > 1 log10 increase in serum HBV DNA from nadir
during treatment in a patient who had an initial
virological response. It is usually also followed by a
biochemical breakthrough. Emergence of anti-viral
resistance can eventually lead to reversion of virologi-
cal and histological improvement, and enhance the
rate of disease progression.6 The best strategy to avoid
the emergence of drug resistance during therapy is
to suppress viral replication strongly.7 A diversity
of viruses (quasispecies), including mutants with
mutations potentially associated with drug resistance,
may exist prior to therapy.8 Moreover, development of
mutant populations is replication-dependent, and
resistance emerges only when replication occurs in the
presence of the drug selection pressure. Complete sup-
pression of viral replication therefore allows little
opportunity for resistance to develop.9 Several studies
have shown that an initial virological response is asso-
ciated with lower rates of anti-viral drug resistance in
HBV patients in the long term (see below). Therefore,
anti-viral therapy, once initiated, should aim to sup-
press viral replication as quickly and completely as
possible.
EARLY HBV DNA RESPONSES TO PREDICT
LONG-TERM RESPONSES AND RESISTANCE
Recently, the importance of HBV DNA responses to
nucleos(t)ide analogues early during the therapy in
predicting sustained response and development of
resistance has become known. In a recently published
study, to determine the optimal time and HBV DNA
level during an early treatment period for the predic-
tion of the response after a 5-year lamivudine treat-
ment, HBV DNA levels at various time periods until
year 5 were measured in 74 HBeAg-positive chronic
HBV patients receiving lamivudine treatment. Seven-
teen patients achieved an ideal response [HBV DNA
level <2000 copies ⁄mL (400 IU ⁄mL), HBeAg serocon-
version, normal alanine aminotransferase levels and
absence of YMDD mutations] at year 5. Receiver oper-
ating characteristic curves showed good predictions as
early as week 4. The areas under the curve for weeks 4
and 16 were 0.89 and 0.94, respectively. Predictive
indices revealed 4 and 3.6 log-copies ⁄mL (2000 and
800 IU ⁄mL, respectively) to be the best cut-off HBV
DNA levels for these two times, respectively. All
patients with HBV DNA levels lower than these respec-
tive cut-off levels at the two times achieved an ideal
response at year 5. Patients with HBV DNA levels
above these cut-off values had 83.8% and 87.7%
chances of not achieving an ideal response at year 5,
respectively.10
HBV DNA responses at week 24 have also been
assessed for predicting long-term responses and resis-
tance development. A phase 3 telbivudine vs. lamivu-
dine study showed that low HBV DNA levels at week 24
were associated with favourable 1-year efficacy
outcomes. Of HBeAg-positive patients at week 24,
41% with undetectable levels of HBV DNA on PCR
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underwent seroconversion by week 52 as compared with
4% of patients with more than 4 log10 copies of HBV
DNA per millilitre. At week 24, in HBeAg-positive
patients in both treatment groups combined, resistance
occurred in only 2% of patients who were negative for
HBV DNA on PCR, compared to 15% of patients with
viral loads above 4 log10 copies ⁄mL. A similar pattern
was evident for HBeAg-negative patients.11
Adefovir dipivoxil leads to a slower suppression of
viraemia than other nucleoside analogues, i.e. lamivu-
dine, entecavir or telbivudine. Therefore, the week 48
time point may be used for predicting resistance to
adefovir therapy.12 In HBeAg-negative patients treated
with adefovir dipivoxil for 192 weeks, patients with
HBV DNA levels 1000 copies ⁄mL after 48 weeks of
therapy had a higher risk (49%) of developing adefovir
resistance at week 192 than patients with a viral load
<1000 copies ⁄mL at week 48 (6%).
Recently, the ‘roadmap concept has been proposed’,
which recommends monitoring of serum HBV DNA
levels to identify outcomes of therapy during nucle-
os(t)ide analogue therapy. Early monitoring of the
virological response to therapy in CHB treated with
oral nucleos(t)ides is essential to identify primary
treatment failure at week 12 and suboptimal
responses at week 24 to modify management accord-
ingly. This roadmap suggests assessment of primary
nonresponse at week 12 and of early predictors of
efficacy at week 24. The failure to achieve a 1 log10
copies ⁄mL decline in viral load after 12 weeks of
therapy is considered a primary nonresponse. It indi-
cates that either there is a compliance issue or that
the medication does not exhibit its anti-viral activity
in a given patient. When a suboptimal response is
identified, anti-viral treatment should be modified.
Many experts would choose to switch to a more
potent nucleos(t)ide analogue at this interval. The
week 12 time point is therefore important to deter-
mine the anti-viral activity of the treatment regimen.
Assessment of early predictors of efficacy has been
suggested at week 24. If at week 24, complete viro-
logical response (PCR negative) is achieved, therapy
should be continued with the same drug; if there is
a partial virological response (HBV DNA ‡300 to
<10 000 copies ⁄mL), a second drug with a different
genetic mutation profile should be added if the ori-
ginal drug had a low genetic barrier or treatment
should be continued beyond 48 weeks with monitor-
ing every 3 months; if there is an inadequate viro-
logical response (‡10 000 copies ⁄mL), more potent
drug should be added and monitoring should be
continued every 3 months.13 However, prospective
testing of this strategy is necessary; also, the timing
of treatment modification may depend on the drug
used and on the kinetics of viral load decay (patients
starting from very high viral load may need addi-
tional weeks of therapy to reach the threshold of
HBV DNA for treatment modification). Also, whether
such a strategy may be applicable to drugs other
than nucleos(t)ide analogues like immunomodulators
is uncertain. Further studies are needed to clarify
these issues.
LIMITATIONS OF CURRENTLY ESTABLISHED
APPROACHES
Limitations with regard to virological responses
(i) Potent nucleos(t)ide analogues have recently
become available. For example, the 4-year data on
entecavir suggest cumulative rates of HBV DNA unde-
tectability exceeding 90% in HBeAg-positive patients
after four years and, a cumulative resistance rate of
<1%.14 Tenofovir also demonstrates potent suppres-
sion, with 93% and 76% of HBeAg-negative and
HBeAg-positive patients having undetectable HBV
DNA, respectively, after 1 year, and no genotypic
resistance.15, 16 However, even when HBV DNA
becomes undetectable, HBeAg seroconversion does not
ensue at proportional frequency. Discrepancies exist
between the degree of viral suppression and HBeAg
seroconversion. These agents have proven to be effec-
tive in suppressing HBV DNA, but, HBeAg seroconver-
sion rates have not improved substantially relative to
those obtained with earlier treatments.
(ii) An nucleos(t)ide analogue(s) that allows for
cessation of therapy with an acceptable rate of subse-
quent relapse is still lacking, especially for HBeAg-
negative patients.
(iii) The rates of inducing HBsAg loss, with the current
nucleos(t)ide analogues are low, with 3% of HBeAg-
positive patients receiving tenofovir16 and 5% of
HBeAg-positive patients receiving entecavir17 achieving
this milestone after 1 and 2 years, respectively.
Limitations with regard to development of
resistance
All long-term nucleos(t)ide analogues are capable of
selecting for resistance, although the resistance
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rates with drugs having a high genetic barrier to
resistance have been low in the follow-up till
now. Nevertheless, these drugs are not entirely free
from a risk of resistance and more resistance
might be encountered as the duration of follow-
up and experiences with these drugs further
increase.
COMBINATION THERAPIES
All the above limitations have led to an interest in
combination regimens for CHB. In theory, at least,
combination therapy might improve upon monother-
apy with regard to any or all of the above limita-
tions. Agents acting through different mechanisms
can provide a more effective viral suppression lead-
ing to more seroconversion, more HBsAg clearance
and more durable off-treatment response and reduce
the risk of viral mutations. This synergy may lead
to a more effective eradication, a shorter duration of
therapy and dose reductions resulting in fewer drug
side-effects. Support for these concepts comes from
the studies in human immunodeficiency virus (HIV)
and chronic hepatitis C (CHC), where combination
therapies have been proven to be more effective
than monotherapy. The potential disadvantages could
be higher costs, increased toxicity and drug interac-
tions. Many options are available for combination
therapies (Table 1).
COMBINATION THERAPY USING
NUCLEOS(T)IDE ANALOGUE(S)
Hypothesis
Although all available nucleos(t)ide analogues target
the viral polymerase, they have different mechanisms
of action on the viral genome replication machinery.18
Depending on the drug, this inhibitory activity can
affect the priming of reverse transcription, viral
minus-strand DNA synthesis or plus-strand DNA syn-
thesis (Figure 1). Lamivudine is mainly an inhibitor of
minus-strand formation, while clevudine has been
shown to affect both minus- and plus-strand DNA
synthesis.19 Adefovir and tenofovir are active on the
priming of reverse transcription as well as on elonga-
tion of viral minus-strand DNA.20, 21 Entecavir inhibits
both minus- and plus-strand DNA synthesis.22 Tel-
bivudine is also supposed to inhibit all three enzy-
matic activities.23 It is unknown if anti-viral potency
is affected by more than one site of inhibition.
The premise of using nucleos(t)ide analogue combi-
nations is that the combination of nucleos(t)ide ana-
logues with different sites of actions could enhance
the response rates, decrease the anti-viral resistance,
prevent the formation of covalently closed circular
DNA (cccDNA) in newly infected cells, decrease the
pool of cccDNA in already chronically infected cells in
a more effective way than monotherapy and all these
effects on HBV replication could result in restoration
of immune response to achieve a sustained control of
viral replication.
Combination of nucleos(t)ide analogues can be used
in two ways:
(i) Simultaneous combination therapy. Both the
nucleos(t)ide analogues are started simultaneously.
(ii) Add-on combination therapy. Adding another
nucleos(t)ide analogue when there has been subopti-
mal response to initial monotherapy at a specified time
point (see above).
Experimental data
It has been shown that anti-viral synergy could be
obtained by combining adefovir, lamivudine and pen-
ciclovir in duck HBV-infected primary hepatocyte cul-
tures.24 In a hepatoma cell line expressing wild-type
HBV, an additive effect was also observed with the
combination of adefovir and thymidine analogues
(lamivudine, emtricitabine and telbivudine).25
Table 1. Types of combination therapies
Two or more nucleos(t)ide analogues
Simultaneous (all nucleos(t)ide analogues started
simultaneously)
Add-on (adding another nucleos(t)ide analogue when there
has been suboptimal response to initial monotherapy at a
specified time point)
Immunomodulators plus nucleos(t)ide analogues
IFNs (standard or peg-IFN) plus nucleos(t)ide analogues
Simultaneous (no precombination phase) with or
without anti-viral continuation in postcombination
phase.
Sequential (a precombination phase) with or without
anti-viral continuation in postcombination phase.
Interleukin 12 plus lamivudine
IFNs plus ribavirin
Thymosine plus IFN plus lamivudine
Two immunomodulators
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One of the major problems of anti-viral therapy of
chronic HBV infection is the effect of anti-HBV
agents on de novo cccDNA formation after viral
entry. Even the combination of amdoxovir, emtricita-
bine and clevudine could not prevent the formation
of cccDNA in experimentally infected primary
hepatocytes.26
Another issue is to determine whether anti-viral
therapy may have an effect on already formed cccDNA
in chronically infected cells, thus resulting in cell cur-
ing. It was shown that a combination of nucleoside
analogues may have an additive effect on the intracel-
lular cccDNA levels in already infected cells, which
suggests that the additive effect observed on viral
3´ 
Viral 
DNA 
Virion 
) + ( (–) ) + ( (–) cccDNA 
Nucleus 
Pol 
) + ( RNA 
5´ 
Assembly of cores
l o P 
HBc Translation 
SRT 
) + ( RNA 
Replication 
complex 
5´ 
5´ 
DNA (–) DNA (–) 
Template shift 
2nd primer shift
1st primer shift
DNA 
plus-strand
synthesis
Clevudine, entecavir,
telbivudine
Adefovir, tenofovir,
Adefovir, tenofovir,
lamivudine, emtricitabine,
DNA minus-strand 
Reverse transcription 
RNase H 
Synthesis
(a) (c)(b)
(f) (d)(e)
entecavir, amodoxovir,
telbivudine
Infection 
DNA repair 
RNA-pregenome 
Cytoplasm 
synthesis 
elvucitabine, entecavir,
telbivudine, clevudine
5´ 
5´ 
Figure 1. Replication of HBV genome and site of action of different anti-viral agents: the virion DNA after entering the cell
nucleus (a) is converted to covalently closed DNA (cccDNA) (b). This episomal DNA is transcribed to various RNAs, one of
which serves as a template for the polymerase protein and HBc protein. These two proteins assemble together with their
mRNA to the replication complex. The encapsidation signal e at its 5¢ end governs the packaging of the RNA and the prim-
ing of the minus-strand DNA (c). The redundant part at 3¢ end serves as a signal for reverse transcription after priming.
The primase domain of the polymerase serves as a primer for the reverse transcription. Thus, the growing minus-DNA
strand is linked at its 5¢ end to the primase (d). The reverse transcription proceeds until the 5¢ end of the RNA template is
reached (e). Thus a short redundancy is generated in the minus-strand. The RNase H activity associated with the reverse
transcriptase degrades the RNA template and leaves at its 5¢ end an 18-base-long capped RNA fragment, which functions
as primer for the plus-strand DNA (f ). The DNA polymerase is able to cross the discontinuity in the minus-strand template
because of its short terminal redundancy. Thereafter, the structure of virion DNA is reproduced. Various nucleoside and
nucleotide analogues act on three different sites: the priming of reverse transcription, elongation of minus-strand DNA or
elongation of plus-strand DNA.
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DNA synthesis may also result in an additive effect on
cccDNA levels.26 Therefore, this implies an important
role of combination therapy to decrease intrahepatic
viral load during long-term therapy.
Clinical data
Clinical responses. In a viral dynamics study com-
paring the effectiveness of HBV viral suppression by
lamivudine monotherapy with that of lamivudine plus
famciclovir simultaneous combination therapy in Chi-
nese patients with chronic HBV infection, 21 Chinese
HBeAg-positive patients, were randomized to receive
either lamivudine 150 mg ⁄day orally (n = 9) or lami-
vudine 150 mg ⁄day plus famciclovir 500 mg three
times a day orally (n = 12) for 12 weeks, with a fol-
low-up period of at least 16 weeks. It was found that
the viral load decay was biphasic in both groups of
patients. Mean log10 HBV viral decline at week 12
were 1.8  0.2 for lamivudine alone group and
2.5  0.8 for the combination group. The mean anti-
viral efficacy was significantly poorer with lamivudine
alone than for lamivudine plus famciclovir
(0.94  0.03 vs. 0.988  0.012, P = 0.0012). The frac-
tion of baseline viral production persisting during
therapy was 1.2% for the combination compared to
6% for lamivudine alone, a difference of fivefold. This
increased efficacy of combination therapy translates
into a larger first phase of 1.9 log10 compared to 1.1
log10 for lamivudine alone. The t1 ⁄ 2 (days) of free HBV
virus and infected cells were similar in both groups
(2.3  1.4 vs. 1.8  1.1 and 37  21 vs. 47  52,
P = not significant).27
The phase 2 trial in nucleos(t)ide naı¨ve HBeAg-posi-
tive patients of telbivudine featured three arms: lamivu-
dine alone, telbivudine alone and telbivudine combined
with lamivudine.28 The degree of viral suppression after
1 year was no greater with combination therapy than
with telbivudine, although each was superior to lamivu-
dine, and combination therapy was actually slightly
inferior to telbivudine monotherapy in attaining thera-
peutic response (HBV DNA <5 log10 copies ⁄mL coupled
with HBeAg loss or normalization of ALT levels) (53%,
77% and 63% for lamivudine, telbivudine and the com-
bination arms, respectively). Although the reasons for
these observations are not clear, it seems wise to avoid
using drugs with cross-resistance, such as lamivudine
and telbivudine, in combination.
A study assessing the combination of emtricitabine
plus clevudine (n = 82) for 24 weeks found that, after
24 weeks post-treatment, higher proportion (30% vs.
14%, P = 0.007) of patients in the combination arm
had HBV DNA<4700 copies ⁄mL along with normal
ALT compared to emtricitabine alone (n = 81). In this
study, 52% of patients were HBeAg-positive and 34%
were treatment-naı¨ve. The safety profile was similar
between arms during treatment, with less post-treat-
ment exacerbation of hepatitis B in the combination
arm.29
In a placebo-controlled study in nucleos(t)ide naı¨ve
HBeAg-positive patients of lamivudine monotherapy
(n = 57) vs. lamivudine plus adefovir (n = 54), reduc-
tions in HBV DNA were comparable between the two
treatment arms at week 16 and during the first
52 weeks, but after 104 weeks, median HBV DNA
reductions were )3.41 log and )5.22 log, respectively.
Similarly, HBV DNA was <200 copies ⁄mL in 41% and
40% at 52 weeks, 14% vs. 26% at 104 weeks and 5 vs.
6% at week 128. HBeAg seroconversion was found in
17% and 10% at 52 weeks, 20% vs. 13% at 104 weeks
and 17 vs. 23 at week 128.30, 31
In yet another study,32 comparing adefovir (n = 16)
alone to a combination of adefovir plus emtricitabine
(n = 14), in treatment-naı¨ve HBeAg-positive patients
for 96 weeks, a significant advantage for combination
therapy was achieved, with median HBV DNA declines
of )3.98 log10 copies ⁄mL vs. )5.30 log10 copies ⁄mL
for monotherapy and combination therapy, respec-
tively, at 96 weeks (P = 0.05), and HBV DNA <300
copies ⁄mL in 37.5% vs. 78.5%. There was no differ-
ence in the incidence of HBeAg seroconversion despite
the difference in viral suppression.
Therefore, combination therapies using nucleos(t)ide
analogues lead to higher viral suppression although it
may not be sustained in long-term therapy or post-
therapy cessation. Also higher suppression of the virus
does not translate into higher rates of seroconversion
in HBeAg-positive patients.
Breakthrough and development of resistance. In the
placebo-controlled study in nucleos(t)ide naı¨ve
HBeAg-positive patients of lamivudine monotherapy
vs. lamivudine plus adefovir,30, 31 a higher rate of
viral breakthrough was seen in the monotherapy
group than in the combination group (44% vs.
19%). In the lamivudine monotherapy group, the
M204V ⁄ I mutation was detected in 20% and 43% at
weeks 52 and 104, compared to 9% and 15% at the
same time points in the combination therapy group.
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The N236T mutation was noted in only one adefovir
recipient.
In the study32 comparing adefovir alone to a combi-
nation of adefovir plus emtricitabine, in treatment-
naı¨ve HBeAg-positive patients for 96 weeks, the four
viral breakthroughs in the study occurred at 64 weeks
and beyond; three of these occurred in the combina-
tion group but none was associated with drug-resis-
tance mutations. Thus, in this study, there was a
complete absence of resistance to emtricitabine. In
contrast, in the emtricitabine monotherapy trial, resis-
tance occurred in 13% at 48 weeks.33
The results of these trial indicate that the addition
of a nucleos(t)ide with a good resistance profile to a
nucleos(t)ide with a lower genetic barrier to resistance
effectively decreases the risk of emergent resistance to
the latter drug.
Summary and future strategies
The situation of anti-HBV therapy is different from the
antiretroviral therapy of HIV infection. The antiretro-
viral drugs belong to several different classes of com-
pounds, which target different steps of the viral life
cycle and HIV drug resistance emerges very rapidly
during monotherapy. The beneficial effect of combina-
tions therefore could be shown in short-term trials in
terms of viral load decline, prevention of drug resis-
tance and decrease in mortality rate.34 In contrast, in
the setting of CHB, anti-virals belong to the same class
of nucleos(t)ide analogues and target the viral poly-
merase (see above). This might be the reason why the
combination of nucleos(t)ide analogues did not show
any long-term additive effect in terms of viraemia
decline compared to the most potent anti-viral drug in
the combination. HBV drug resistance emerges rela-
tively slowly compared to HIV infection. Several drugs
with different cross-resistance profiles are now avail-
able. Clinical experience has shown that the combina-
tion of nucleoside analogues with complementary
cross-resistance profile is an effective strategy to man-
age patients developing resistance during nucleos(t)ide
therapy.35 Obviously, these observations cannot be
extrapolated to the question of how frequently resis-
tance will emerge when the two drugs are co-adminis-
tered to treatment-naı¨ve patients. The newer
nucleos(t)ide analogues (entecavir, tenofovir, etc.) have
a robust resistance profile in nucleos(t)ide naive
patients during the first few years of therapy. The ben-
efit of combination therapy in terms of decreasing the
resistance development will therefore be difficult to
demonstrate in short-term trials. Therefore, future tri-
als of combination therapy should target the following
three groups of patients. (i) Patients with the highest
risk of resistance development during therapy with
nucleos(t)ide analogues; for example, patients with
long-standing infection and high viraemia levels
associated with more complex viral populations
(quasispecies), which are associated with a more rapid
hepatocyte turn-over, in turn generating a wider repli-
cation space.36, 37 (ii) Patients who can least afford to
develop anti-viral drug resistance from a clinical per-
spective; for example, patients with liver cirrhosis
and ⁄or with HBV recurrence after liver transplantation.
(iii) When there has been suboptimal response to ini-
tial monotherapy at a specified time point, such as
24 weeks of a drug with a low genetic barrier to
resistance or 1 year of a drug with a high barrier (i.e.
add-on combination therapy). Individual features and
limitations of the individual agents incorporated into
combination regimens need to be considered. Addi-
tional trials of combination therapy of anti-virals
using potent nucleos(t)ide analogues with robust long-
term resistance profiles, for treatment-naı¨ve HBV
infection are warranted, emphasizing on serological
and virological endpoints, such as greater rates of
HBV DNA suppression, HBeAg seroconversion, HBsAg
clearance, accelerated cccDNA clearance, development
of resistance and the capacity to stop therapy without
virological relapse at a definable time point. Also, tri-
als comparing combination therapy vs. early add-on
therapy in case of partial response should be con-
ducted and both these strategies should be compared
to monotherapy with the most potent nucleos(t)ide
analogues, such as entecavir and tenofovir.
Combinations of nucleos(t)ide analogues with drugs
with other mechanisms of action, such as immunomod-
ulatory agents, small interfering RNAs (siRNAs), etc.,
have also been tried as combination therapies in CHB.
IFNS PLUS NUCLEOS(T)IDE ANALOGUES
Hypothesis
IFNs have only mild virus-suppressive activity, but
can induce an effective host immune response in sus-
ceptible patients, whereas nucleos(t)ide analogues have
a marked virus-suppressive activity in a majority of
patients, but have not been shown convincingly to
have clinically relevant immunomodulatory effects.
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Therefore, the combination of the two could possibly
provide both viral suppression and immunmodulation
and hence increase the response rate. The results of
such combination therapies have been mixed. Vari-
ability of the results could be due to variability in the
three potential phases of the combination therapies
(Figure 2).
Combination therapies of nucleos(t)ide analogues
and immunomodulators can have three phases: Pre-
combination phase, combination phase and postcombi-
nation phase (Figure 2). One or more of them could be
clubbed to achieve the desired results.
Precombination phase. Adding a precombination
phase could qualify for a sequential therapy. During
this phase of treatment, either of the drugs (i.e. nucle-
os(t)ide analogues or immunomodulator) is used alone,
at least once.
Combination phase. During this phase, both the nu-
cleos(t)ide analogues and the immunomodulator are
used together throughout the treatment period.
Postcombination phase. In this phase, either nucle-
os(t)ide analogues are continued or no therapy is
given.
When there is no precombination phase, it is called
simultaneous combination therapy. The approach in
combination therapy with the precombination phase
merits to be called ‘sequential combination therapy’.
With the ‘sequential combination therapy’, an impor-
tant issue remains unanswered; whether to use a nu-
cleos(t)ide analogue or an immunomodulator in the
precombination phase. The hypothesis for the use of
sequential combination therapy using nucleos(t)ide
analogues in the precombination phase is that a low
pre-treatment serum HBV DNA level is associated with
an increased probability of response to IFN-a. The
most important factor known to predict favourable
response to IFN-a is low baseline HBV DNA lev-
els.18, 19 It has been shown that the decrease in viral
load induced by lamivudine therapy is associated with
the subsequent restoration of the CD4 and then the
CD8 cellular immune response against HBV.38
Enhanced T-cell reactivity is observed with rapid and
profound suppression of HBV DNA levels.39 Lowering
HBV DNA levels by lamivudine before starting peg-
IFN has been shown to be superior to using peg-IFN
alone.40
Another important issue is whether to continue nu-
cleos(t)ide analogues in the postcombination phase.
The premise of continuing anti-virals in the postcom-
bination phase is that prolonged use of nucleos(t)ide
analogues has been shown to improve therapeutic
response, suppress and eliminate the cccDNA and
maintain seroconversion.41
Theoretically, the ideal combination therapy could
be one that uses nucleos(t)ide analogues in precombi-
nation phase to reduce the circulating virus prior to
introducing immunomodulators, immunomodulate to
kill cells having virus and continue viral suppression
with anti-virals in the postcombination phase to
reduce reinfection of new hepatocytes.
Clinical data
Clinical responses. Efficacy of simultaneous standard
IFN plus lamivudine in HBeAg-positive treatment-
naı¨ve CHB patients. Trials examining use of standard
IFN- and lamivudine in simultaneous combination, in
treatment-naı¨ve HBeAg-positive patients have shown
that combination therapy had a greater on-treatment
viral suppression and higher rates of sustained off-
treatment response than lamivudine alone, but no dif-
ference in sustained off-treatment response compared
to IFN-a alone (Table 2).
Efficacy of sequential lamivudine and standard IFN
in HBeAg-positive treatment-naı¨ve CHB patients. There
are only a few clinical trials, which have used sequen-
tial therapy with lamivudine in the precombination
phase.42, 47 Similarly, there are limited trials which
have used a maintenance phase of lamivudine treat-
ment following the combination therapy.47 The trial of
Precombination
or
orand
Combination Postcombination
Nucleos(t)ide analogues Nucleos(t)ide analogues Nucleos(t)ide analogues alone
Immunomodulator Immunomodulator
No therapy
Figure 2. The three phases of
combination therapies with
anti-viral and immuno-
modulators.
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Schalm et al.,42 which used sequential therapy without
continuing lamivudine in the postcombination phase,
found higher rates of sustained off-treatment response
compared with lamivudine alone, but no difference in
the sustained off-treatment response compared to IFN-
a alone. The trial by Sarin et al.,47 which used sequen-
tial therapy with continued lamivudine in the post-
combination phase, did not have a treatment arm of
IFN alone for the sake of comparison to answer
whether continuing anti-virals in the postcombination
phase is useful or not.
Efficacy of simultaneous peg-IFN plus lamivudine in
HBeAg-positive CHB patients. The simultaneous com-
bination of lamivudine and peg-IFN has shown higher
rates of sustained off-treatment response than lamivu-
dine alone, but with no statistical difference in the
sustained off-treatment response compared to peg-IFN
alone (Table 3). In one study,58 peg-IFN monotherapy
was compared to 48 weeks of lamivudine monothera-
py or the combination of lamivudine and peg-IFN. The
end of treatment decline in HBV DNA was more robust
in patients treated with the combination therapy the
values being )7.2 log, )4.5 log and )5.8 log, respec-
tively, for combination therapy, peg-IFN alone and
lamivudine monotherapy. However, combination ther-
apy was not more effective in achieving sustained
virological response at the end of a 24-week follow-up
period. HBeAg seroconversion occurred more fre-
quently in patients with on treatment ALT flares.62
In another study,59 peg-IFN-a-2b was given in a
dose of 100 lg weekly for 32 weeks followed by 50 lg
weekly until completion of 52 weeks of treatment. This
treatment arm was compared to the identical dose and
duration of peg-IFN given simultaneously with
52 weeks of lamivudine. There was a greater decline in
HBV DNA in the combined group (approximately )5
log vs. )2 log) as well as a higher rate of HBeAg loss
(44% vs. 29%) at the end of treatment. However, these
differences were not sustained during a 26-week fol-
low-up period. The reasons for this discrepancy are
unclear but the modification in dosage at the 32-week
treatment interval could have been a contributing ele-
ment. HBsAg loss occurred in 5% of the peg-IFN
monotherapy group and 7% of the combined therapy
patients. Further analyses of the data demonstrated that
the rate of HBeAg clearance was the highest (58%,
P = 0.008) in patients who experienced ALT flares.63
Similarly, in a study evaluating the effect of peg-
IFN or its combination with lamivudine on liver his-
tology of 110 patients with HBeAg-positive CHB,
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Table 3. Pegylated-IFN plus lamivudine in HBeAg-positive chronic hepatitis B
Author
(reference)
Study
design Location Regimens
ETR
Undetectable
levels of
serum HBV
DNA
HBeAg())
and anti-HBe(+)
ALT
normalization
HBeAg()),
serum HBV
DNA <5
log-copies ⁄mL
and ALT
normalization
Histologic
response
Lau
et al.58
RCT Multi Simultaneous HBV DNA <400
copies ⁄mL
Peg-IFN-a-2a
180 lg ⁄weeks
+ placebo
(n = 271) · 48 weeks
25 27 39 10
Peg-IFN-a-2a
180 lg ⁄weeks + L
100 mg ⁄ day
(n = 271) · 48 weeks
69 24 46 15
L 100 mg ⁄ day
(n = 272) · 48 weeks
40 20 62 18
Janssen
et al.59
RCT Multi Simultaneous DNA < 400
copies ⁄mL
Peg-IFN-a-2b
100 lg ⁄week · 32 weeks,
then 50 lg ⁄week till
52 weeks + L
100 mg ⁄ day ·
52 weeks (n = 130)
33 25 51 48
Peg-IFN-a-2b +
placebo · 52 weeks
(n = 136)
10 (P < 0.001) 22 (P = 0.52) 34 (P = 0.005) 53 (P = 0.57)
Chan
et al.60
RCT China Sequential
Peg-IFN-a-2b
1.5 lg ⁄ kg ⁄weeks ·
8 weeks, then
peg-IFN + L
100 mg ⁄ day ·
24 weeks, then
L · 28 weeks (n = 48)
60
L 100 mg ⁄ day ·
52 weeks (n = 47)
28 (P = 0.001)
Chan
et al.61
RCT China Sequential HBeAg loss, anti-
HBe appearance
and HBV DNA,
500 000
copies ⁄mL
Peg-IFN-a-2b 8 weeks
administered, then
peg-IFN + L
100 mg ⁄ day ·
24 weeks, then
L · 28 weeks (n = 50)
60 90
L 100 mg ⁄ day ·
52 weeks (n = 50)
28 (P < 0.001) 78
Only significant P-values are indicated (as compared to L). ETR, end of treatment responses; L, lamivudine; SVR, sustained viral responses.
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YMDD
Viral
resistance
Primary
treatment
failure F ⁄ U
SVR
Undetectable
serum HBV DNA
HBeAg())
and
anti-HBe(+)
ALT
normalization
HBeAg()),
serum HBV
DNA <5
log-copies ⁄mL
and ALT
normalization
Histological
response
24 weeks
14 (P < 0.001) 32 (P < 0.001) 41 (P = 0.002) 23 (P < 0.001) 49
4 (P < 0.001) 14 (P < 0.001) 27 (P = 0.02) 39 (P = 0.006) 21 (P < 0.001) 52
27 5 19 28 10 51
26 weeks DNA < 400
copies ⁄mL
11 9 29 35
7 (0.43) 29 (P = 0.92) 32 (P = 0.60)
Sustained response: HBeAg loss and HBV DNA <100 000 copies ⁄mL from treatment cessation
until the end of follow-up
Combination:
117  34
weeks
29.2
L: 124  29
weeks
8.5 (P < 0.05)
24 weeks HBeAg loss, anti-HBe
appearance and HBV
DNA 500 000 cop-
ies ⁄mL
36 50 10
14 (P = 0.011) 30 9
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treated for 52 weeks with peg-IFN-a-2b in simultaneous
combination with either lamivudine or placebo found
that treatment with peg-IFN therapy improved liver
necro-inflammation and fibrosis in HBeAg-positive
CHB patients, particularly in responders to therapy. The
addition of lamivudine to peg-IFN did not further
improve the histological outcome. In the peg-IFN ⁄
lamivudine combination therapy group, no significant
association between virological and biochemical end-
points and histological improvement was observed.64
Efficacy of sequential peg-IFN plus lamivudine
in HBeAg-positive CHB patients. Chan et al.60
using sequential approach of peg-IFN and lamivu-
dine with peg-IFN alone for 8 weeks of precom-
bination phase with a total of 32-week course of
peg-IFN-a-2a combined with 52 weeks of lamivudine
found a sustained response of 36% in combination
arm and 14% in lamivudine alone arm. Unfortu-
nately, this study also did not have a peg-IFN alone
limb.
Efficacy of simultaneous standard IFN plus lamivu-
dine in HBeAg-negative CHB. Trails of simultaneous
standard IFN plus lamivudine in HBeAg-negative CHB
have also yielded negative results (Table 4).
Table 4. Standard IFN plus lamivudine in HBeAg-negative chronic hepatitis B
Author
(reference)
Type of
combination Location
Combination
regimen
Comparison
regimen
Response
definition
Sustained
response
Combination
arm (%)
Sustained
response
Comparison
arms (%) P
Manesis et al.65 Sequential Greece L 100 mg ⁄ day
from 1 to
12 months
and IFN-a-2b
from 7 to
18 months
(n = 36)
IFN-a-2b
(historical
control)
(n = 36)
ALT
normalization
and serum
HBV DNA
levels
£30 000
copies ⁄mL
22.2 13.9 N.S.
Tatulli et al.66 Simultaneous Italy IFN-a 6 MU
TIW + L ·
52 weeks
(n = 29)
– Undetectable
serum HBV
DNA and ALT
normalization.
14
Economou
et al.67
Simultaneous Greece IFN-a-2b 5 MU
TIW and L
100 mg ⁄ day ·
24 months
(n = 24)
L 100
mg ⁄ day ·
24 months
(n = 26)
Undetectable
serum HBV
DNA and ALT
normalization
21 12 N.S.
Yurdaydin
et al.68
Sequential Turkey L · 2 months,
then L and
IFN 9 MU,
TIW ·
10 months
L 100
mg ⁄ day ·
12 months
Undetectable
HBV DNA
27 25 N.S.
Santantonio
et al.69
Simultaneous Italy IFN-a 5 MU
TIW and L
100 mg ⁄
day ·
12 months
(n = 24)
L 100
mg ⁄ day ·
12 months
(n = 26)
Undetectable
serum HBV
DNA and ALT
normalization
17 19 N.S.
Karabay
et al.70
Simultaneous Turkey IFN-a 9 MU
TIW · 24
weeks and L
100 mg ⁄
day · 1 year
(n = 14)
IFN-a 9 MU
TIW · 24
weeks
(n = 13)
Undetectable
HBV DNA
50 38 N.S.
L, lamivudine.
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However, in a recent study from Greece, 36 anti-
HBe-positive patients were treated with IFN (3 MU
subcutaneously three times weekly) and lamivudine
(100 mg orally once a day) for 12 months. After com-
pletion of the combined treatment, all patients contin-
ued to receive lamivudine monotherapy indefinitely.
Overall, 35 patients (97%) showed virological response
at 12 months. Four patients (11%) cleared HBsAg and
developed anti-HBs. During the follow-up time, after
the discontinuation of IFN, of 30  12 months, 13
patients (36%) exhibited ‘break-through’ infection. The
cumulative rates of break through infection at the end
of 1, 2, 3 and 4 years of treatment were 0%, 14%,
32% and 59%, respectively. Combination therapy
appeared to be effective and may also delay the selec-
tion of lamivudine-resistant variants.71
Efficacy of sequential lamivudine plus standard IFN
in HBeAg-negative CHB. Manesis et al.65 in a sequen-
tial study design with lamivudine first but without
postcombination phase with lamivudine found similar
responses with the sequential vs. IFN monotherapy.
Yurdaydin et al.68 in a sequential study design with
lamivudine first but without postcombination phase
with lamivudine found similar responses with the
sequential vs. lamivudine alone therapy.
Efficacy of simultaneous peg-IFN plus lamivudine
in HBeAg-negative CHB. Marcellini et al. found that
a simultaneous combination of peg-IFN plus lamivu-
dine for 48 weeks was better than peg-IFN alone or
lamivudine alone.72 However, another small study
found that simultaneous combination of peg-IFN
plus lamivudine for 48 weeks was no better than
peg-IFN alone.73
Efficacy of sequential peg-IFN plus lamivudine in
HBeAg-negative CHB. In a small study sequential ther-
apy with lam and peg-IFN was found to be no better
than lam alone (Table 5).74
In a meta-analysis, comparing IFN and lamivudine
vs. IFN for HBeAg-positive patients, it was found that
greater sustained virological, biochemical and serocon-
version rates were observed with addition of lamivu-
dine to conventional [odds ratio (OR) = 3.1, 95%
confidence intervals (CIs): 1.7–5.5, P < 0.0001;
OR = 1.8, 95% CI: 1.2–2.7, P = 0.007 and OR = 1.8,
95% CI: 1.1–2.8, P = 0.01, respectively], although not
pegylated (OR = 1.1, 95% CI: 0.5–2.3, P = 0.8;
OR = 1.0, 95% CI: 0.7–1.3, P = 0.94 and OR = 0.9,
95% CI: 0.6–1.2, P = 0.34, respectively) IFN-a, with no
significant effect on HBeAg clearance rates (OR = 1.6,
95% CI: 0.9–2.7, P = 0.09 and OR = 0.8, 95%
CI: 0.6–1.1, P = 0.26, respectively). This meta-analysis,
which was not restricted to treatment-naı¨ve subjects,
concluded that, in comparable populations, peg-IFN
monotherapy is likely to be equally or more effica-
cious than conventional IFN and lamivudine combina-
tion therapy, thus constituting the treatment of choice,
with no added benefit with lamivudine addition. How-
ever, when conventional IFN is used, its combination
with lamivudine should be considered.75
In another meta-analysis, comparing lamivudine
and lamivudine vs. IFN for HBeAg-positive patients, it
was found that greater sustained virological, biochem-
ical and seroconversion rates with the addition of con-
ventional (OR = 4.5, CI: 2.2–9.4, P < 0.001; OR = 2.1,
95% CI: 1.3–3.2, P = 0.002 and OR = 2.6, 95% CI:
1.4–4.8, P = 0.001, respectively) and pegylated
(OR = 2.0, 95% CI: 1.1–3.6, P = 0.02; OR = 1.8, 95%
CI: 1.3–2.6, P < 0.001 and OR = 1.6, 95% CI: 1.1–2.3,
P = 0.03, respectively) IFN-a to lamivudine, with the
former also yielding greater hepatitis Be antigen clear-
ance rates (OR = 2.6, 95% CI: 1.3–5.2, P = 0.008).
Peg-IFN monotherapy and its combination with lami-
vudine were comparable; the use of this combination
is not justified. In contrast, when conventional IFN is
used, its combination with lamivudine should be con-
sidered.76
Breakthrough and development of resistance. The
combination of peg-IFN and nucleos(t)ide analogues
seems to reduce the rates of viral resistance. Lau
et al.58 found that 27% of those receiving a 48-week
course of lamivudine monotherapy had detectable
YMDD mutations vs. 4% of those on both peg-IFN-2a
plus lamivudine. Janssen et al.59 found that 6% of
patients receiving combination therapy who entered
the trial without a pre-existing YMDD mutant devel-
oped such a mutation by the end of the 48-week
treatment period. This is substantially lower than the
15–32% rates of viral resistance at 1 year observed in
patients receiving lamivudine monotherapy. A recent
Korean study investigated the effects of IFN-a com-
bined with lamivudine on the occurrence of viral
breakthrough during long-term lamivudine therapy.
Eighty-three patients with CHB were randomly allo-
cated to a combination of lamivudine and IFN-a
(n = 41) or lamivudine only (n = 42), and then fol-
lowed up for >12 months. There was no difference
in cumulative rates of undetectable serum HBV
DNA (100% vs. 100% at 24 months, P = 0.13) and
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Table 5. Pegylated-IFN plus lamivudine in HBeAg-negative chronic hepatitis B
Author
(reference)
Study
design Location Regimens
ETR
Undetectable
serum HBV
DNA
ALT
normalization
Serum HBV
DNA <400
copies ⁄mL and
ALT
normalization
Marcellin
et al.72
RCT Multi Stimultaneous HBV DNA <400
copies ⁄mL
Peg-IFN-a-2a
180 lg ⁄weeks +
placebo (n = 177)
· 48 weeks
63 38 27
Peg-IFN-a-2a
180 lg ⁄weeks + L
100 mg ⁄ day
(n = 179) · 48 weeks
87 49 46
L 100 mg ⁄ day
(n = 181) · 48 weeks
73 73 60
Kaymakoglu
et al.73
RCT Turkey Simultaneous HBV DNA
<4 pg ⁄mL
Peg-IFN-a-2b
1.5 lg ⁄ kg ⁄weeks ·
48 weeks (n = 19)
63 53
Peg-IFN-a-2b
1.5 lg ⁄ kg ⁄weeks + L
100 mg ⁄ day · 48 weeks
(n = 29)
79 66
Vassiliadis
et al.74
RCT Greece Sequential HBV DNA <400
copies ⁄mL
L 100 mg ⁄ day alone
for 3 months, then
L and peg-IFN-a-2b
(100 mg s.c. once
weekly) for 3 months
and then peg-IFN-a-2b
alone for 9 months
(n = 18)
88* 72.2
L100 mg ⁄ day · at
least 15 months
(n = 24)
70.8 70.8
Only significant P-values are indicated (compared to L); L, lamivudine.
* Response occurred significantly earlier in the sequential combination treatment group (median time to response, 6 months vs.
12 months, P < 0.05.
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YMDD
Viral
resistance
Primary
treatment
failure F ⁄U
SVR
Histological
improvement
Undetectable
serum HBV
DNA
ALT
Normalization
Serum HBV
DNA <400
copies ⁄mL
and ALT
normalization
Histologic
response
24
weeks
HBV DNA
<400
copies ⁄mL
19 (P < 0.001) 59
(P = 0.004)
15
(P = 0.007)
55
1
(P < 0.001)
20 (P < 0.001) 60
(0.0003)
16
(P = 0.003)
46
18 7 44 6 46
24
weeks
HBVDNA
<400
copies ⁄mL
26 42
24 48
12
months
HBV DNA
<400
copies ⁄mL
33.3 72.2 33.3
16.7 25 (P < 0.01) 12.5
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cumulative rates of serum HBeAg loss between the
combination and the lamivudine group (49%, 61% and
67% vs. 31%, 39% and 42%, respectively, at 12, 24
and 36 months; P = 0.07). The cumulative occurrence
rate of viral breakthrough, however, was significantly
lower in the combination group than in the lamivu-
dine group (5%, 20% and 30% vs. 10%, 55% and
58%, respectively, at 12, 24 and 36 months;
P = 0.006). From the patients with viral breakthrough,
YMDD mutants were detected in 82% of the lamivu-
dine group in contrast with 56% of the combination.
Thus IFN-a combined with lamivudine may reduce
viral breakthrough during long-term lamivudine ther-
apy, probably by suppressing the appearance of YMDD
mutants.77
Summary and future strategies
Greater on treatment viral suppression occurs when
peg-IFN and lamivudine are taken together compared
with that of either agent alone. As far as response
rates are concerned, peg-IFN monotherapy is likely
to be equally or more efficacious than conventional
IFN and lamivudine combination therapy, with no
added benefit with lamivudine addition. However,
when conventional IFN is used, its combination with
lamivudine may be considered at least in HBeAg-
positive CHB patients. A separate analysis comparing
simultaneous vs. sequential combination therapies is
warranted. The resistance to lamivudine is lower
with combination therapy. A high rate of HBsAg
clearance has been reported when adefovir is used
with peg-IFN in a small pilot study. In this study
(adefovir was combined with peg-IFN-a-2b, both
administered for 48 weeks), the rate of HBeAg sero-
conversion (53%) as well as that of HBsAg serocon-
version (15%) were higher when compared with
historical cohorts.78
Whether the lack of synergy between IFNs and lami-
vudine against HBV is specific to this drug combina-
tion or reflects a more fundamental flaw in the
rationale of combining an immunomodulatory agent
and a nucleoside analogue is yet to be explored.
Because nucleos(t)ide analogues work slowly in pro-
moting HBeAg seroconversion, the results of combina-
tion therapy should be compared with the nucleoside
analogue alone given for a suitably long period of
time. Studies combining peg-IFN with other more
potent anti-virals such as entecavir, and tenofovir in
different types of combination regimens, are needed to
address these issues.
INTERLEUKIN-12 (IL-12) PLUS LAMIVUDINE
Hypothesis
The diversity of clinical out comes after exposure to
HBV is determined primarily by the host immune
response.79 In contrast to the strong anti-viral T-cell
reactivity in acute hepatitis B, patients with chronic
HBV infection have weak or undetectable T-cell reac-
tivity to HBV. T cells control HBV replication by
noncytolytic anti-viral effects primarily mediated by
IFN-gamma (IFN-c).80 IL-12 stimulates natural killer
cells and T-lymphocytes to produce IFN-c, promotes
T-helper 1 responses, and enhances CD8 cytotoxic
T-cell activity. These unique properties of IL-12 indi-
cate that it might have an important role in achieving
sustained control of HBV replication.81
Experimental data
The administration of recombinant IL-12 to HBV
transgenic mice resulted in complete inhibition of
HBV replication in the liver and undetectable vira-
emia, mediated through IFN-c induction.82 In addition,
IL-12 restored in vitro the hypo-responsiveness to viral
antigens of T cells obtained from patients with CHB.83
Clinical data
In a pilot study, 15 patients with HBeAg-positive CHB
were randomized to receive either lamivudine alone for
24 weeks (group 1); combination of lamivudine for
16 weeks and recombinant human-interleukin-12
(rhIL-12) (200 ng ⁄kg twice weekly), starting 4 weeks
after initiation of lamivudine, for 20 weeks (group 2),
or the same schedule as for group 2, with lamivudine
and a higher dose of rhIL-12 (500 ng ⁄kg, group 3).
Lamivudine plus higher dose rhIL-12 showed a greater
anti-viral activity than lamivudine monotherapy. How-
ever, after stopping lamivudine in groups 2 and 3,
serum HBV DNA increased significantly despite contin-
uing rhIL-12 administration. Lamivudine plus rhIL-12
treatment was associated with a greater increase in
virus-specific T-cell reactivity, IFN-c production. There-
fore, the addition of IL-12 to lamivudine enhances
T-cell reactivity to HBV and IFN-c production.84
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STANDARD IFN PLUS RIBAVIRIN
Hypothesis
A major advancement in treating hepatitis C virus
infection has been the development of combination
therapy with IFN and ribavirin. IFN monotherapy is
limited by poor sustained virological responses, even
when higher doses are used. In contrast, IFN ⁄ ribavirin
combination therapy results in much-improved sus-
tained remission rates.85, 86 Ribavirin and IFN in com-
bination has been used for the treatment of dual CHB
and CHC.87 After about 2 year post-treatment follow-
up, 21% of the responsive patients also cleared hepati-
tis B surface antigen.88 It has recently been shown that
ribavirin and IFN-a combination therapy induces CD4+
T-cell proliferation and Th1 cytokine secretion in
patients with CHB.89
Clinical data
However, in a study, for the treatment of HBeAg-posi-
tive CHB, adding ribavirin did not increase the efficacy
of IFN.90
THYMOSIN PLUS IFN PLUS LAMIVUDINE
In a study in China, 74 patients with HBeAg-positive
CHB were divided into three groups: sequential com-
bination group (patients received 8 weeks of thymo-
sin a1, 6 months of IFN begun in the fifth week,
and lamivudine begun 2 months later after HBeAg
seroconversion or just after the withdrawal of IFN,
to more than 18 months =30), simultaneous combi-
nation group (patients received 6 months IFN and
thymosin a1 simultaneously in the same manner as
in sequential anti-viral group; n = 14) and lamivu-
dine group (patients received more than 18-month
treatment with lamivudine = 30). HBeAg seroconver-
sion, undetectable HBV DNA and normalization of
ALT were seen in 76.7%, 57.1% and 16.7% among
the three groups, respectively (P < 0.01). Sequential
anti-viral therapy had much higher rates of long-
term efficacy. Mechanisms to promote the anti-viral
effect might be dependent on the immunoregulatory
action of thymosin a1 in the earlier period and the
specific inhibition of HBV DNA replication by lami-
vudine in the later period of the therapeutic
course.91
COMBINATION THERAPY USING SIRNAS
Hypothesis
siRNAs are a class of 20–25 nucleotide-long double-
stranded RNA molecules that play a variety of roles in
biology. These are involved in the RNA interference
(RNAi) pathway where the siRNA interferes with the
expression of a specific gene, and also act in RNAi-
related pathways, e.g. as an anti-viral mechanism or
in shaping the chromatin structure of a genome. A
combination of siRNAs targeting different sites of HBV
transcripts could have additive effects.
Experimental data
In a study to evaluate the inhibitory effect mediated
by combination of siRNAs targeting different sites of
HBV transcripts on the viral replication and antigen
expression in vitro, seven siRNAs targeting surface (S),
polymerase (P) or precore (PreC) region of HBV gen-
ome were designed and chemically synthesized. HBV-
producing HepG2.2.15 cells were treated with or with-
out siRNAs for 72 h. Synthetic siRNAs targeting S and
PreC gene could efficiently and specifically inhibit
HBV replication and antigen expression. The expres-
sion of HBsAg and HBeAg and the replication of HBV
could be specifically inhibited in a dose-dependent
manner by siRNAs. Furthermore, the combination of
siRNAs targeting various regions could inhibit HBV
replication and antigen expression in a more efficient
way than the use of single siRNA at the same final
concentration.92
COMBINATION THERAPY USING TWO
IMMUNOMODULATORS
Hypothesis
Immunomodulators other than IFNs such as thymosine
a and anti-HBV vaccine have been found to be useful
in treatment of CHB. It is possible that a combination
of two immunomodulators would be more effective
than either of them alone.
Thymosin a1 plus IFN
A study from Singapore compared the combination of
thymosin a1 and lymphoblastoid IFN (combination
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therapy; n = 48) with thymosin alone (monotherapy;
n = 50), for 24 weeks in naı¨ve HBeAg-positive CHB
patients with raised ALT. The HBeAg loss at
72 weeks was 45.8% and 28.0% for combination
therapy and monotherapy, respectively (P = 0.067)
showing a trend towards HBeAg loss when using
combination therapy. There were no statistically
significant differences between the two therapies
with respect to HBeAg seroconversion, changes in
histology, normalization of ALT or loss of HBV
DNA.93
Vaccine plus IFNs
In a Turkish study, 50 treatment-naı¨ve children with
CHB were randomly assigned to receive either IFN-
a-2b for 9 months, and pre-S2 ⁄S vaccine at the
beginning and 4 and 24 weeks after initiation of IFN
therapy (n = 25) or recombinant IFN-a-2b alone for
9 months (n = 25). The mean HBV DNA values were
significantly reduced in combination group at the end
of the therapy (P = 0.004), but no statistically signifi-
cant difference was found 6 months after the end of
treatment. Sustained HBeAg seroconversion with clear-
ance of HBV DNA was obtained in 13 (52%) treated
with combination therapy, and in eight (32%) treated
with IFN monotherapy (P = 0.251).94
SUMMARY
In summary, the answer to the question whether hepa-
titis B can be treated better with combination or
monotherapy remains largely unknown. There is how-
ever no doubt that today we have entered an era
where monotherapies alone seem to have plateaued in
their efficacy. There is an urgent need to evaluate
combination of peg-IFN and potent oral nucleos(t)ide
analogues or the combined use of nucleos(t)ide ana-
logues or immunomodulators. The possibility of multi-
drug combinations such as in HIV should also be
explored. These strategies and newer drugs targeting
alternative sites of viral replication and their combina-
tions will ultimately allow us to treat CHB with more
confidence.
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